# SARCLISA® (isatuximab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/isatuximab

> SARCLISA® (isatuximab), sponsored by Sanofi (SNY): 2 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | SARCLISA® (isatuximab) |
| Codes |  |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | [Relapsed/Refractory Multiple Myeloma](https://sec-api.dev/indications/relapsed-refractory-multiple-myeloma) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### December 22, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Relapsed/Refractory Multiple Myeloma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05704049 (A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-12-22 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT05704049

### July 23, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-04-23, last confirmed 2026-04-27.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-180848): "The revised target action date for the FDA decision is July 23, 2026." https://www.sec.gov/Archives/edgar/data/1121404/000119312526180848/d137048dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001121404-26-000004): "The revised target action date for the FDA decision is July 23, 2026." https://www.sec.gov/Archives/edgar/data/1121404/000112140426000004/pressreleaseq12026english.htm

Calendar months: [July 2026](https://sec-api.dev/fda-calendar/2026-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/isatuximab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SARCLISA® (isatuximab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/isatuximab

```bibtex
@misc{secapidev_pdufa_isatuximab_20261116,
  title        = {SARCLISA® (isatuximab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/isatuximab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_isatuximab_20261116","title":"SARCLISA® (isatuximab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/isatuximab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
